This episode is from the European Cancer Congress that took place in Vienna, Austria from September 25-29, 2015.

Prof Tom Powles ECC 2015 Atezolizumab

You will hear leading experts talk about the latest cancer immunotherapy data. Professor Tom Powles (Barts, London) discusses the exciting data presented for renal and bladder cancer.

Dr Martin Reck (Grosshansdorf, near Hamburg) talks about the lung cancer immunotherapy data presented in Vienna and the new checkpoint inhibitor data at the meeting. He offers his perspective on the importance of quality-of-life in clinical decision making, and what role biomakers may play in Europe.

We’ve published commentary and analysis about the latest “Controversies in Lung Cancer Immunotherapy” on Biotech Strategy Blog (subscription required).

Dr Nora Disis (University of Washington, Seattle) takes us through her ovarian cancer poster and offers insights into how we may get checkpoints to work better in tumors that are not hypermutated (like melanoma, renal, bladder) but are immunogenic i.e. able to elicit an immune response.

This episode features excerpts from an interview with Dr Holbrook Kohrt who was leading the way in researching the potential of immune agonists targeting 4-1BB (CD137). It is with great sadness that we must report that since this episode aired, Holbrook Kohrt is no longer with us. He died, aged 38, on February 24, 2016.

Dr Holbrook Kohrt Stanford

In-Memorium Holbrook Kohrt